Personalized oncology medicine

19/06/2013

Nathan Nagel and Dr Scott M. Kahn

In our oncology focus month, Nathan Nagel and Dr Scott Kahn discuss how the new era of personalized medicine is going to change the lives of cancer patients in years...

ASCO analysis: market access challenges in Europe for PD-1/PD-L1 targe…

19/06/2013

Christine Henry and Richard Wagner

Christine Henry and Richard Wagner of Kantar Health offer their opinions of the market access landscape for oncology in Europe following the recent 2013 ASCO annual meeting.Therapies that target the...

Addressing the challenge of cancer trial accrual

18/06/2013

Edwin Watson

Edwin Watson highlights the challenge of cancer trial accrual in our oncology themed month, and questions how we can encourage physicians to refer more patients to oncology clinical trials. The Current...

Sanofi Oncology pipeline update 2013

18/06/2013

Dr Tal Zaks

pharmaphorum's Hannah Blake catches up with Dr Tal Zaks from Sanofi Oncology to see where the global pharma company's oncology pipeline is heading, the unique partnerships that have helped Sanofi...

AZ, BMS diabetes drug fails to reduce heart risks

19/06/2013

Hannah Blake

AstraZeneca and Bristol-Myers Squibb have announced disappointing results of their diabetes drug, Onglyza, which failed to reduce heart risks in phase 4 clinical trials.The SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes...

Sanofi, Curie-Cancer enter ovarian cancer collaboration

19/06/2013

Hannah Blake

Sanofi and the Curie Institute, through its Curie-Cancer partnership, have announced the establishment of a three-year research collaboration to identify new therapeutic targets for the development of ovarian cancer treatments.The...

GSK receives offer for thrombosis brands

18/06/2013

Hannah Blake

GSK has received an offer from South African pharma company, Aspen, and it's wholly owned subsidiary, Aspen Global Incorporated, for its thrombosis brands and Notre-Dame de Bondeville (NDB) manufacturing site...

Lilly assumes development rights to potential type 2 diabetes drug

18/06/2013

Hannah Blake

Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate, TT-401, from Canada's Transition Therapeutics, who will receive a...

Perspectives on personalised healthcare …

Executive perspectives: Bruno Strigini

Doctors hold the key to understanding pa…

Carly Brown

Pharma is recognising the increasing importance of the patient voice in providing feedback on how medicines are utilised in a real-world setting and the impact they are having on outcomes....

Outcomes shape the new payer networks fo…

Marcelo Fantoni

The definition of the payer and the way in which healthcare spending decisions are made is changing, as complex networks of payers and clinicians become the new stakeholders with which...

Publishing white papers on pharmaphorum

Paul Tunnah

As a new feature on pharmaphorum, we unveil pharmaceutical industry white papers as part of our media section. Download this one page document to understand how to publish your deep...